Point-of-care STI tests provide results near the site of care, typically within minutes to an hour, enabling clinical decisions during the same visit.
2
FDA-cleared, CLIA-waived molecular assays can detect chlamydia and gonorrhea in about 20 minutes, with accuracy approaching laboratory-based testing.
3
Same-visit results can reduce dependence on follow-up, which is especially important for people facing barriers to care or at increased risk of being lost to follow-up.
4
Point-of-care testing may reduce empiric treatment and unnecessary antibiotic exposure, while supporting antimicrobial stewardship.
5
Implementation challenges include cost, operational complexity, specimen-type restrictions, workflow demands, and the need for staff training and quality oversight.